Murat Celebi is meeting innovative MedTech companies at CIRSE2019 – is international expansion in your strategy? Murat Celebi, Clinical Marketing Director, is in Barcelona on the 9th and 10th of September at CIRSE2019, meeting established clients as well as MedTech companies looking to expand internationally. Whether you are an established player in your own country or a growing startup... Source ..read more

We are counting down to BAUS 2019 in Glasgow next week. Will you be in Glasgow this year? If so, visit us on Stand 445 between 24-26 June to find out more about the EMDA® Bladder Cancer Treatment. EMDA® has been proven to significantly prolong the disease-free interval and reduce the risk of recurrence in high and intermediate-risk patients with NMIBO (non-muscle invasive bladder cancer). Source ..read more

Physion has appointed JS Consulting as their strategic advisor for the GCC & Middle East regions. JS Consulting is delighted to announce it will be working with Physion s.r.l of Italy to advise on the company’s expansion in the Middle East and Gulf regions. The two organisations have successfully worked together for several years in the United Kingdom, with JS Medical (previously known... Source ..read more

During his recent visit to Azerbaijan to introduce RenalGuard® to clinicians in Baku, Robin Luper was delighted to be invited to speak to AZ Television as part of their coverage of the introduction of this specialised treatment for cardiology patients. The reportage included details of the successful first case, including an interview with the delighted patient (no English translation available). Source ..read more

JS Medical will be exhibiting the EMDA® drug delivery system at BAUS Brighton. Following the publication of the latest trial results from the Urology group at Guy’s & St Thomas’ NHS Foundation Trust, JS Medical will be demonstrating the EMDA® treatment package at the BAUS Section of Oncology Meeting in Brighton from 21 to 22 November 2019. The study cites: Source ..read more

Latest data from Guy’s & St Thomas’ endorses intravesical sequential BCG/EMDA+MMC for HR-NMIBC Recent data presented by the Urology group from Guy’s & St Thomas’ NHS Foundation Trust in London, suggests that the use of a sequential intravesical regimen of BCG/EMDA+MMC after TURBT may be a useful alternative strategy in bladder preservation for HR-NMIBC patients who fail BCG. Source ..read more

REMEDIAL III trial results presented at TCT2019 in San Franciso by Dr Carlo Briguori. RenalGuard Solutions announced on 3 October 2019 that a late-breaking clinical trial has found the company’s RenalGuard Therapy® is superior to the POSEIDON method in preventing contrast-induced acute kidney injury (CI-AKI) for patients with kidney disease who undergo interventional procedures. Source ..read more

RenalGuard Solutions has appointed JS Medical as their new UK and Ireland distributor. JS Medical is delighted to be appointed as the UK and Ireland distributor for the RenalGuard Therapy® technology, designed to reduce the incidence of Contrast-Induced Nephropathy found in the millions of at-risk patients undergoing cardiovascular imaging procedures by managing real-time fluid balance in... Source ..read more

EuroPCR 2019 proved as informative as ever with Robin Luper delighted to share the benefits of the RenalGuard System with new contacts as well as catching up with colleagues. For more information on RenalGuard, please contact Robin Luper on +44 ()1234-888955 or by email via info@js-group.global. About RenalGuard Therapy® RenalGuard measures a patient’s urine output and automatically infuses... Source ..read more

NICE has called for EMDA® to be used in research programmes as a treatment for bladder cancer. Following an interventional procedure overview of the EMDA® (Electromotive Drug Administration) treatment in June 2018, NICE issued updated guidance for clinicians in England and Wales on 30 January 2019. The guidance recommends that EMDA® should be used as part of research studies treating Non-Muscular... Source ..read more